 Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. MelphalanHDS has not been approved by the U.S. Food Drug Administration FDA for sale in the U.S. In Europe, our system is marketed under the trade name Delcath Hepatic CHEMOSAT Delivery System for Melphalan CHEMOSAT and has been used at major medical centers to treat a wide range of cancers of the liver. 